Efficacy and Safety of Romiplostim N01 for Injection in Promoting Platelet Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation

Inclusion Criteria: * 1.Subjects must understand study procedures, be willing to comply with the study protocol, and provide written informed consent prior to any study-related procedures. 2\. Age ≥18 years, male or female. 3. Patients with hematological malignancies undergoing allogeneic hematopoietic stem-cell transplantation (allo-HSCT). 4\. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 5. Adequate organ function defined as follows: * Serum bilirubin ≤ 2 mg/dL, unless due to benign congenital hyperbilirubinemia; * AST, ALT and alkaline phosphatase \< 3 × upper limit of normal (ULN); * Creatinine clearance ≥ 40 mL/min (calculated by the Cockcroft-Gault formula); * Left ventricular ejection fraction (LVEF) ≥ 45% by MUGA scan or resting echocardiogram; * Pulmonary function: FEV1 and corrected DLCO ≥45% of predicted value. 6. Participants of reproductive potential must use reliable contraceptive methods throughout the study period (including male or female condoms, contraceptive foam, contraceptive gel, contraceptive diaphragm, contraceptive cream, contraceptive suppositories, abstinence, intrauterine device, etc.). Exceptions include female participants who have undergone hysterectomy, bilateral salpingectomy, bilateral tubal ligation, or are postmenopausal for more than 1 year; and male participants with bilateral vasectomy. Exclusion Criteria: * 1\. Subjects who have received romiplostim, eltrombopag, or other TPO-RA thrombopoietic agents within 1 month prior to enrollment. 2\. History of symptomatic or incidental venous thromboembolic events (e.g., deep vein thrombosis or pulmonary embolism), except patients who received and tolerated anticoagulation within the preceding 6 months, completed anticoagulation \>6 months ago, or are receiving ongoing anticoagulation. Patients with central venous catheter-related venous thromboembolic events are excluded. 3\. Patients with a history of symptomatic arterial thrombotic events including myocardial infarction, ischemic cerebrovascular accident, or transient ischemic attack within the preceding 6 months. 4\. Patients with severe underlying diseases that may interfere with the conduct of the study, such as unstable angina, renal failure requiring hemodialysis, or active infection requiring intravenous antibiotic therapy. 5\. Abnormal hepatic or renal function: total bilirubin \> 2 × upper limit of normal (ULN); AST or ALT \> 1.5 × ULN; creatinine \> 1.5 × ULN; estimated glomerular filtration rate \< 30 mL/min/1.73 m². 6\. Patients with positive hepatitis C antibody plus elevated HCV-RNA; patients with positive hepatitis B surface antigen plus elevated HBV-DNA; patients with severe liver cirrhosis; patients with positive HIV antibody or positive syphilis antibody. 7\. Subjects with known hypersensitivity or intolerance to the active ingredient or excipients of injectable Romiplostim N01. 8.Participation in any other interventional clinical study of investigational drugs or devices within 1 month prior to screening. 9\. Female subjects who are pregnant or breastfeeding. 10. Subjects who, in the investigator's judgment, are unable to comply with study procedures, or for whom study participation is otherwise deemed inappropriate by the investigator.